These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 31341124)

  • 21. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE; Loochtan AI; Bedlack RS
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis.
    Zhao S; Zhou Y; Sun W; Li Z; Wang C
    Clin Exp Immunol; 2023 Mar; 211(2):85-92. PubMed ID: 36426591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nivolumab-related myasthenia gravis with myositis requiring prolonged mechanical ventilation: a case report.
    Saishu Y; Yoshida T; Seino Y; Nomura T
    J Med Case Rep; 2022 Feb; 16(1):61. PubMed ID: 35152911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immune checkpoint inhibitor-induced anti-striational antibodies in myasthenia gravis and myositis: a case report].
    Sugiyama Y; Esa Y; Watanabe A; Kobayashi J; Suzuki S; Takahashi D
    Rinsho Shinkeigaku; 2021 Sep; 61(9):630-634. PubMed ID: 34433744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
    Cham J; Ng D; Nicholson L
    J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of late-onset, thymoma-associated myasthenia gravis with ryanodine receptor and titin antibodies and concomitant granulomatous myositis.
    Stefanou MI; Komorowski L; Kade S; Bornemann A; Ziemann U; Synofzik M
    BMC Neurol; 2016 Sep; 16(1):172. PubMed ID: 27623618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
    Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
    Chen JH; Lee KY; Hu CJ; Chung CC
    Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune-Biological Evaluation and Case Report.
    Botta C; Agostino RM; Dattola V; Cianci V; Calandruccio ND; Bianco G; Mafodda A; Maisano R; Iuliano E; Orizzonte G; Mazzacuva D; Falzea AC; Saladino RE; Giannicola R; Restifo G; Aguglia U; Caraglia M; Correale P
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Fatal Case of Immune Checkpoint Inhibitor-Mediated Myasthenia Gravis, Myositis, and Cardiomyopathy Overlap Syndrome in Urothelial Carcinoma.
    Newman MT; Bikhchandani M
    Cancer Rep (Hoboken); 2024 Jul; 7(7):e2140. PubMed ID: 39041627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myositis and myasthenia during nivolumab administration for advanced lung cancer: a case report and review of the literature.
    Veccia A; Kinspergher S; Grego E; Peterlana D; Berti A; Tranquillini E; Caffo O
    Anticancer Drugs; 2020 Jun; 31(5):540-544. PubMed ID: 32011360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cascade of immunologic adverse events related to pembrolizumab treatment.
    Dhenin A; Samartzi V; Lejeune S; Seront E
    BMJ Case Rep; 2019 Jun; 12(6):. PubMed ID: 31167767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myositis as a neuromuscular complication of immune checkpoint inhibitors.
    Vermeulen L; Depuydt CE; Weckx P; Bechter O; Van Damme P; Thal DR; Claeys KG
    Acta Neurol Belg; 2020 Apr; 120(2):355-364. PubMed ID: 31993961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-Kv1.4 Antibody-positive Nivolumab-induced Myasthenia Gravis and Myositis Presenting with Bilateral Ptosis and Demonstrating Different Pathophysiologies.
    Kitazaki Y; Yamamura O; Usui K; Ueno A; Sanada S; Sasaki H; Endo Y; Enomoto S; Ikawa M; Nakamoto Y; Hamano T
    Intern Med; 2023; 62(20):3013-3020. PubMed ID: 37839874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review.
    Hasegawa Y; Kawai S; Ota T; Tsukuda H; Fukuoka M
    Immunotherapy; 2017 Aug; 9(9):701-707. PubMed ID: 28649876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
    Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
    Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
    [No Abstract]   [Full Text] [Related]  

  • 37. Immune checkpoint inhibitors (ICIs)-related ocular myositis.
    Garibaldi M; Calabrò F; Merlonghi G; Pugliese S; Ceccanti M; Cristiano L; Tartaglione T; Petrucci A
    Neuromuscul Disord; 2020 May; 30(5):420-423. PubMed ID: 32387281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of myositis with dropped head syndrome and anti-titin antibody positivity induced by pembrolizumab.
    Takahashi S; Mukohara S; Hatachi S; Yamashita M; Kumagai S
    Scand J Rheumatol; 2020 Nov; 49(6):509-511. PubMed ID: 32914675
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
    Puwanant A; Isfort M; Lacomis D; Živković SA
    Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report].
    Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K
    Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.